Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.42) per share which met the analyst consensus estimate. This is a 16 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $715.000 thousand which missed the analyst consensus estimate of $2.075 million by 65.54 percent.
Iovance Biotherapeutics Q1 2024 GAAP EPS $(0.42), Inline, Sales $715.000K Miss $2.075M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.